33 preclinical and clinical targets with **STRONG GENETIC SUPPORT**

The industry's largest toolkit with **13** **MODALITIES***

A mix of **INNOVATIVE MOLECULES, NEW INDICATIONS, AND BIOSIMILARS**

A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.

PHASE ONE

AMG 176 Hematology/ Oncology	AMG 211 Hematology/ Oncology	AMG 224 Hematology/ Oncology
AMG 301 Neuroscience	AMG 330 Hematology/ Oncology	AMG 420 Hematology/ Oncology
AMG 557 Inflammation	AMG 570 Inflammation	AMG 592 Inflammation
AMG 820 Hematology/ Oncology	AMG 986 Cardiovascular	IMLYGIC® (talimogene laherparepvec) Hematology/ Oncology
KYPROLIS® (carfilzomib) Hematology/ Oncology	Oprozomib Hematology/ Oncology	

PHASE TWO

AMG 899 Cardiovascular	BLINCYTO® (blinatumomab) Hematology/ Oncology	Erenumab Neuroscience
Tezepelumab Inflammation		

PHASE THREE

AMG 520 Neuroscience	Aranesp® (darbepoetin alfa) Hematology/ Oncology	BLINCYTO® (blinatumomab) Hematology/ Oncology
Enbrel® (etanercept) Inflammation	Erenumab Neuroscience	**EVENITY™ (romosozumab) Bone Health
IMLYGIC® (talimogene laherparepvec) Hematology/ Oncology	KYPROLIS® (carfilzomib) Hematology/ Oncology	Omecamtiv mecarbil Cardiovascular
Prolia® (denosumab) Bone Health	Repatha® (evolocumab) Cardiovascular	Vectibix® (panitumumab) Hematology/ Oncology
XGEVA® (denosumab) Hematology/ Oncology		

BIOSIMILARS‡

ABP 215 (biosimilar bevacizumab) Hematology/ Oncology	ABP 494 (biosimilar cetuximab) Hematology/ Oncology	ABP 710 (biosimilar infliximab) Inflammation	ABP 798 (biosimilar rituximab) Hematology/ Oncology & Inflammation	ABP 959 (biosimilar eculizumab) Hematology /Oncology	ABP 980 (biosimilar trastuzumab) Hematology/ Oncology

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.
***Tradename provisionally approved by the United States Food and Drug Administration,*

This information reflects public disclosures current as of April 7, 2017. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE ONE	Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.		
MOLECULE NAME & PRONUNCIATION	**MODALITY**	**THERAPEUTIC AREA**	**DESCRIPTION**
AMG 176	**Small Molecule**	**Hematology/ Oncology**	AMG 176 is a small molecule being investigated as a treatment for multiple myeloma.
AMG 211	**BiTE® Antibody**	**Hematology/ Oncology**	AMG 211 is an anti-CEA x anti-CD3 (BiTE®) bispecific antibody construct. It is being investigated as a treatment for various cancer types. AMG 211 is being jointly developed in collaboration with MedImmune.
AMG 224	**Antibody Drug Conjugate**	**Hematology/ Oncology**	AMG 224 is an antibody drug conjugate being investigated for the treatment of multiple myeloma.
AMG 301	**Monoclonal Antibody**	**Neuroscience**	AMG 301 is a human monoclonal antibody that inhibits the type 1 receptor of the pituitary adenylate cyclase-activating polypeptide (PAC1). It is being investigated for migraine prevention. AMG 301 is being jointly developed in collaboration with Novartis.
AMG 330	**BiTE® Antibody**	**Hematology/ Oncology**	AMG 330 is an anti-CD33 x anti-CD3 (BiTE®) bispecific antibody construct. It is being investigated as a treatment for acute myeloid leukemia.
AMG 420	**BiTE® Antibody**	**Hematology/ Oncology**	AMG 420 is an anti-BCMA x anti-CD3 (BiTE®) bispecific antibody construct. It is being investigated as a treatment for multiple myeloma.
AMG 557	**Monoclonal Antibody**	**Inflammation**	AMG 557 is a human monoclonal antibody that inhibits the action of B7 related protein (B7RP-1). It is being investigated as a treatment for systemic lupus erythematosus. AMG 557 is being jointly developed in collaboration with AstraZeneca.
AMG 570	**Bispecific Antibody**	**Inflammation**	AMG 570 is a bispecific antibody-peptide conjugate that targets BAFF and ICOSL. It is being investigated as a treatment for systemic lupus erythematosus. AMG 570 is being jointly developed in collaboration with AstraZeneca.
AMG 592	**Fusion Protein**	**Inflammation**	AMG 592 is an IL-2 mutein Fc fusion protein. It is being investigated as a treatment for inflammatory diseases.
AMG 820	**Monoclonal Antibody**	**Hematology/ Oncology**	AMG 820 is a human monoclonal antibody that inhibits c-fms and decreases tumor-associated macrophage (TAM) function. It is being investigated as a treatment for various cancer types.
AMG 986	**n/a**	**Cardiovascular**	AMG 986 is being investigated for the treatment of heart failure.
IMLYGIC® (talimogene laherparepvec) *tal im' oh jeen la her" pa rep' vek*	**Oncolytic Immunotherapy**	**Hematology/ Oncology**	IMLYGIC® is an oncolytic immunotherapy derived from HSV-1. It is being investigated as a combination treatment in patients with mid- to late-stage metastatic melanoma (Phase 1b/3) and in other cancer types (Phase 1).

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of April 7, 2017. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE ONE

Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
KYPROLIS® (carfilzomib) *car fil' zoe mib*	**Small Molecule**	**Hematology/ Oncology**	KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma and as a treatment for small-cell lung cancer (Phase 1b/2).
Oprozomib *oh proz' oh mib*	**Small Molecule**	**Hematology/ Oncology**	Oprozomib is an oral proteasome inhibitor. It is being investigated for the treatment of multiple myeloma.

PHASE TWO

Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 899	**Small Molecule**	**Cardiovascular**	AMG 899 is a small molecule cholesteryl ester transfer protein (CETP) inhibitor. It is being investigated for the treatment of dyslipidemia.
BLINCYTO® (blinatumomab) *blin" a toom' oh mab*	**BiTE® Antibody**	**Hematology/ Oncology**	BLINCYTO® is an anti-CD19 x anti-CD3 (BiTE®) bispecific antibody construct. It is being investigated for the treatment adult patients with relapsed/refractory Philadelphia chromosome-positive (Ph+) and minimal residual disease of ALL (Phase 2), and for adult patients with diffuse large B cell lymphoma (DLBCL) (Phase 2). In March 2017, Amgen announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO® to include overall survival (OS) data from the Phase 3 TOWER study. The application also includes new data supporting the treatment of patients with Philadelphia chromosome-positive (Ph+) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). BLINCYTO® is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
Erenumab	**Monoclonal Antibody**	**Neuroscience**	Erenumab is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide. It is being investigated for the treatment of episodic migraine (Phase 3) and chronic migraine (Phase 2). Erenumab is being jointly developed in collaboration with Novartis.
Tezepelumab	**Monoclonal Antibody**	**Inflammation**	Tezepelumab (formerly AMG 157) is a human monoclonal antibody that inhibits the action of TSLP. It is being investigated as a treatment for asthma and atopic dermatitis. Tezepelumab is being jointly developed in collaboration with AstraZeneca.

PHASE THREE

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 520	**Small Molecule**	**Neuroscience**	AMG 520 (CNP520) is a small molecule inhibitor of BACE. It is being investigated for the prevention of Alzheimer's Disease. AMG 520 (CNP520) is being jointly developed in collaboration with Novartis.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of April 7, 2017. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

Aranesp® (darbepoetin alfa) *dar" be poe' e tin al fa*	**Therapeutic Protein**	**Hematology/ Oncology**	Aranesp® is a recombinant human protein agonist of the erythropoietin receptor. It is being investigated as a treatment for low risk myelodysplastic syndromes.

PHASE THREE

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
BLINCYTO® (blinatumomab) *blin" a toom' oh mab*	**BiTE® Antibody**	**Hematology/ Oncology**	BLINCYTO® is an anti-CD19 x anti-CD3 (BiTE®) bispecific antibody construct. It is being investigated as a treatment for adult patients with relapsed/refractory Philadelphia chromosome-positive (Ph+) and minimal residual disease of ALL (Phase 2), and for adult patients with diffuse large B cell lymphoma (DLBCL) (Phase 2). In March 2017, Amgen announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO® to include overall survival (OS) data from the Phase 3 TOWER study. The application also includes new data supporting the treatment of patients with Philadelphia chromosome-positive (Ph+) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). BLINCYTO® is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
Enbrel® (etanercept)	**Fusion Protein**	**Inflammation**	ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis, as well as a monotherapy in maintaining remission of rheumatoid arthritis.
Erenumab	**Monoclonal Antibody**	**Neuroscience**	Erenumab is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide. It is being investigated for the treatment of episodic migraine (Phase 3) and chronic migraine (Phase 2). Erenumab is being jointly developed in collaboration with Novartis.
EVENTIY™ (romosozumab) *roe" moe soz' ue mab*	**Monoclonal Antibody**	**Bone Health**	EVENITY™ is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being investigated as a treatment for postmenopausal osteoporosis and male osteoporosis. EVENITY™ is being jointly developed in collaboration with UCB. In December 2016, Amgen and UCB announced that we submitted an application to the Pharmaceuticals and Medical Devices Agency in Japan, together with our joint venture partner Astellas Pharma, Inc., seeking marketing approval for EVENITY™ for the treatment of osteoporosis for those at high risk of fracture. In September 2016, Amgen and UCB announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for EVENITY™ for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2017, as a goal for the completion of its review of our application. EVENITY™ is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of April 7, 2017. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

IMLYGIC® (talimogene laherparepvec) *tal im' oh jeen la her" pa rep' vek*	**Oncolytic Immunotherapy**	**Hematology/ Oncology**	IMLYGIC® is an oncolytic immunotherapy derived from HSV-1. It is being investigated as a combination treatment in patients with mid- to late-stage metastatic melanoma (Phase 1b/3) and in other cancer types (Phase 1).

PHASE THREE	**Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.**		
MOLECULE NAME & PRONUNCIATION	**MODALITY**	**THERAPEUTIC AREA**	**DESCRIPTION**
KYPROLIS® (carfilzomib) *car fil' zoe mib*	**Small Molecule**	**Hematology/ Oncology**	KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma and as a treatment for small-cell lung cancer (Phase 1b/2).
Omecamtiv mecarbil *om" e kam' tiv me kar' bil*	**Small Molecule**	**Cardiovascular**	Omecamtiv mecarbil is a small molecule activator of cardiac myosin. It is being investigated for the treatment of chronic heart failure. Omecamtiv mecarbil is being jointly developed in collaboration with Cytokinetics. Amgen has also entered into an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of Independent States, including Russia.
Prolia® (denosumab) *den oh sue' mab*	**Monoclonal Antibody**	**Bone Health**	Denosumab is a human monoclonal antibody that inhibits RANKL. It is being investigated for the treatment of glucocorticoid-induced osteoporosis.
Repatha® (evolocumab) *e" voe lok' ue mab*	**Monoclonal Antibody**	**Cardiovascular**	Repatha® is a human monoclonal antibody that inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). It is being evaluated as a treatment for patients with hyperlipidemia. Repatha® is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
Vectibix® (panitumumab) *pan i tu mue' mab*	**Monoclonal Antibody**	**Hematology/ Oncology**	Vectibix® is a human monoclonal antibody antagonist of the epidermal growth factor receptor (EGFr). It is being investigated as a cancer treatment in patients with chemorefractory, wild-type KRAS exon 2 metastatic colorectal cancer.
XGEVA® (denosumab) *den oh sue' mab*	**Monoclonal Antibody**	**Hematology/ Oncology**	Denosumab is a human monoclonal antibody that inhibits RANKL. It is being investigated as a treatment for the delay or prevention of bone metastases in patients with adjuvant breast cancer (Phase 3).

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of April 7, 2017. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

BIOSIMILARS	A biosimilar, or follow-on biologic, is a biologic medicine designed to have active properties similar to one that has previously been licensed. Biosimilars follow a different regulatory review pathway than innovative products and indications.		
MOLECULE NAME	**MODALITY**	**THERAPEUTIC AREA**	**DESCRIPTION**
ABP 215 (biosimilar bevacizumab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 215 (biosimilar bevacizumab) is an anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody. The reference product primary conditions are colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, breast cancer and ovarian cancer. In December 2016, Amgen and Allergan announced that they a submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215. In November 2016, Amgen and Allergan announced that they submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215. Amgen is developing ABP 215 in collaboration with Allergan.
ABP 494 (biosimilar cetuximab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 494 (biosimilar cetuximab) is an anti-epidermal growth factor receptor (anti-EGFr) monoclonal antibody. It is in pre-clinical development. The reference product primary conditions are colorectal cancer and head and neck cancer. Amgen is developing ABP 494 in collaboration with Allergan.
ABP 710 (biosimilar infliximab)	**Monoclonal Antibody**	**Inflammation**	ABP 710 (biosimilar infliximab) is an anti-tumor necrosis factor-alpha (anti-TNF) monoclonal antibody. The reference product primary conditions are rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis and ankylosing spondylitis.
ABP 798 (biosimilar rituximab)	**Monoclonal Antibody**	**Hematology/ Oncology & Inflammation**	ABP 798 (biosimilar rituximab) is an anti-CD20 monoclonal antibody. The reference product primary conditions are non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. Amgen is developing ABP 798 in collaboration with Allergan.
ABP 959 (biosimilar eculizumab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 959 (biosimilar eculizumab) is a monoclonal antibody that specifically binds to the complement protein C5. The reference product primary conditions are Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS).
ABP 980 (biosimilar trastuzumab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 980 (biosimilar trastuzumab) is an anti-HER2 monoclonal antibody. The reference product primary conditions are HER2+ breast cancer and HER2+ gastric cancer. Amgen is developing ABP 980 in collaboration with Allergan.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of April 7, 2017. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.